In the gene expression/survival study utilizing RNA‐Sequence data of ER+ BC patients who received endocrine therapy, we identified a statistically significant association between the high expression of NANOG and poor overall survival (OS) of ER+ BC patients, particularly prominent in the subgroup of patients with HER2+ status. The gene discussed is ERBB2; the disease is breast cancer.